

Supplementary information

# Nanohydroxyapatite-mediated imatinib delivery for specific anticancer applications

Paulina Sobierajska <sup>1,\*</sup>, Anna Serwotka-Suszczak <sup>2</sup>, Damian Szymanski <sup>1</sup>, Krzysztof Marycz <sup>2,3,4</sup>, and Rafal J. Wiglusz <sup>1,3,\*</sup>

<sup>1</sup> Institute of Low Temperature and Structure Research, Polish Academy of Sciences, Okolna 2, 50-422 Wrocław, Poland; d.szymanski@intibs.pl

<sup>2</sup> Department of Experimental Biology, Wrocław University of Environmental and Life Sciences, Norwida 27B street, A7 building, 50-375 Wrocław, Poland; anna.serwotka-suszczak@upwr.edu.pl (A.S.-S.); krzysztofmarycz@interia.pl (K.M.)

<sup>3</sup> International Institute of Translational Medicine, Malin, Jesionowa 11, 55-114 Wisznia Mała, Poland

<sup>4</sup> Faculty of Veterinary Medicine, Equine Clinic-Equine Surgery, Justus-Liebig-University, 35392, Giessen, Germany

\* Correspondence: p.sobierajska@intibs.pl (P.S.); r.wiglusz@intibs.pl (R.J.W.); Tel.: +48-071-3954-274 (P.S.); +48-071-3954-159 (R.J.W.)

Academic Editor: Derek J. McPhee

Received: 9 September 2020; Accepted: 7 October 2020; Published: 9 October 2020

## 2. Results and discussion

### 2.1. Characterisation of nHAp, Imatinib and nHAp/Imatinib




Figure S1. Time dependent of imatinib release from the drug loaded nHAp/IM.

### 3. Materials and Methods

#### 3.3. Absorption spectroscopy




Figure S2. Evaluation of imatinib (Analyte) concentration in the nHAp/IM (4-fold dilution in relation to the stock solution).